Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapies especially in oncology. As the number of such drugs increases, there will be more and more demand for diagnostics which will predict which patients will benefit from which drug. Our Companion Diagnostics Partner Program is designed to help pharmas and biotechs by providing a breadth of assays and platforms that can be leveraged for the development of new diagnostics. Our genetic platforms include next gen sequencing, Sanger sequencing and qPCR. At Life Technologies, we are uniquely positioned to provide pharmas with flexible, strategic and cost-effective means to develop and commercialize drugs with companion diagnostics.